F-FDG PET/CT were retrospectively identified January 2016-June 2017 in a tertiary hospital in Korea. Of these, two patients were diagnosed with microscopic polyangitis and Kikuchi's disease and one patient was transferred to another hospital. Of five patients whose diagnoses were not confirmed, four patients received non-steroidal anti-inflammatory drug and/or low dose steroid and symptoms disappeared. Our study suggests that outcome of patients with FUO whose 18 F-FDG PET/CT finding is non-diagnostic would be favorable.
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Brief Communication
Positron emission tomography/computerized tomography (PET/CT) is a functional image modality using its ability to metabolize glucose and concentrate specific molecules that have been labeled with a positron-emitting radionuculide. 18 F-2-deoxy-2fluoro-D-glucose ( 18 F-FDG), a glucose analog tagged with a positron-emitting isotope of fluorine, is taken up by metabolically active cells such as malignant cells. This metabolic activity is measured using standardized uptake value (SUV) and is expressed in images. This unique characteristic of 18 F-FDG PET/CT may be used for differential diagnosis of fever of unknown origin (FUO).
18
F-FDG PET/CT was helpful in approximately 50% of patients with FUO [1] [2] [3] . In a prospective study performed in Germany, 18 F-FDG PET/CT was non-diagnostic for 43.3% (104/240) of patients with FUO or inflammation of unknown origin. These non-diagnostic findings included 30% (72/240) of false positive results that were non-specific uptakes [4] . However, prognosis, diagnostic and therapeutic strategies have not been known in patients (2) duration of fever for at least three weeks (3) uncertain diagnosis after three days of study in the hospital [5] . Complete blood cell count (including differential count), peripheral blood morphology, and routine blood work (lactic dehydgrogenase, bilirubin, and liver enzyme), urinalysis with microscopy, blood and urine culture, antinuclear antibodies, rheumatoid factor, human immunodeficiency virus antibody, chest radiography, and hepatitis serology were done as first-level work-up [6] . Enhanced computerized tomography and transthoracic echocardiography were done as second-level work-up. We recommended 18 F-FDG PET/CT as a second-level work-up for patients with FUO when diagnosis was not confirmed after these tests were done. All patients fasted for at least six hours whose blood glucose level was less than 140 mg/dL before administration of 18 F-FDG PET/CT. After intravenous injection of body weight-adapted 18 F-FDG (4.4 MBq/kg), patients rested for 60 minutes. PET/CT images were acquired from mid-thigh to vertex of the skull. PET data were acquired by using of twothree minutes per bed position and field of view of 700 mm. CT was conducted by low dose non-enhanced and dose reducing protocol (100 KeV) and reconstructed with SAFIRE (Sinogram Affirmed Iterative Reconstruction) with slice thickness of 3 mm. Attenuation corrected axial PET images (4.07 × 4.07 × 3 mm) were reconstructed using 3D OSEM (two iterations, 21 subsets) with Siemens UltraHD PET. Scans were conducted using an integrated PET/CT system (Biograph mCT 128; Siemens Healthcare, Knoxville, TN, USA). A nuclear medicine physician analyzed PET/CT images under the knowledge of patient's clinical history and other imaging studies. Data on demographics (age, sex), abnormal findings (laboratory, radiologic, and pathologic findings), treatment, final diagnosis, and outcome (resolution of symptoms) were searched. Results of F-FDG-PET/CT was normal but a specific disease process could be detected with another diagnostic test or response to specific treatment, (4) False positives, 18 F-FDG-PET/CT showed tracer uptake that could not be identified as the cause of FUO by additional tests [4] .
A total of eight patients with FUO who had complaints of non-specific symptoms such as fever, chills, myalgia, and headache underwent 18 F-FDG PET/CT during the study period. Clinical characteristics, 18 F-FDG PET/CT findings, and outcomes are summarized in Table 1 Ga SPECT/CT [8] . High sensitivity of 18 F-FDG PET/CT has resulted in high false positive rate [4, 8] . Our study also showed the presence of non-specific findings not leading to diagnosis in six (75%) patients. Clinical implication of false positive results of 18 F-FDG PET/CT is currently unknown. Nonetheless, high sensitivity might be useful as a tool for decision making of FUO based on good prognosis in undiagnosed patients with FUO. Revest et al. have also insisted that symptoms of patients experiencing FUO with negative firstline investigations and negative 18 F-FDG PET/CT almost always disappear spontaneously despite the lack of evidence [9] . In our study, only two (25%) patients had true positive finding in 18 F-FDG PET/CT. Compared to previous studies on diagnostic usefulness of 18 F-FDG PET/CT in FUO [1] [2] [3] [4] 10] , its contribution to diagnosis for FUO was low. A possible explanation is that different populations are used between the present study and previous studies. 18 F-FDG PET/CT has high contribution rate in patients finally diagnosed as malignancy [1, 11] . Based on these previous results, it can be assumed that contribution rate of 18 F-FDG PET/CT in FUO might be higher in studies that included more patients with malignancy. In our study, no one had malignancy. This might have resulted in a low contribution rate of 18 F-FDG PET/CT. Another possible explanation is the relatively short follow-up duration in our study. This might have led to the inclusion of more patients with spontaneous resolution but less patients with delayed diagnosis in the study. When more patients with spontaneous resolution are included, the diagnostic contribution of 18 F-FDG PET/CT is lower. Although 18 F-FDG PET/CT had a low contribution to diagnosis for FUO, it would be still valuable to evaluate its usefulness as "fast-tract" work-up for diagnosis of FUO. Analyzing the safety and cost-benefit of conducting 18 F-FDG PET/CT as a second-level work-up that may replace other tests is necessary in the future. This study has limitations. It is a small-size retrospective study. The number of enrolled patients are insufficient for conclusive results. In addition, owing to its retrospective nature, there is possibility of miss-categorization of FUO. Short-term followup period was also a significant limitation not to ensure outcome of enrolled patients. Finally, it was impossible to compare with patients who were not tested by 18 F-FDG PET/CT, because our study was single-arm descriptive study.
In conclusion, outcome of patients with FUO whose 18 F-FDG PET/CT finding is non-diagnostic seems to be favorable. Well-designed prospective trials should be conducted to establish 18 F-FDG PET/CT-guided diagnostic/treatment strategies for FUO.
